Home›Articles›How a Head-to-Head Trial Made the Case for Encorafenib in MelanomaArticleHow a Head-to-Head Trial Made the Case for Encorafenib in MelanomaArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnEncorafenib, Drugs and Medicinal Substances Well-attested SourcesEncorafenib (Wikipedia)tier 2WikipediaPharmacology section (mechanism); History section (COLUMBUS trial); Medical uses section (approval timeline)Quote, Pharmacology section (mechanism); History section (COLUMBUS trial); Medical uses section (approval timeline)The median PFS was 14.9 months for participants receiving binimetinib plus encorafenib, and 7.3 months for the vemurafenib monotherapy armView the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.